WinterWyman Executive Search Places Senior Director of Human Resources at Alnylam Pharmaceuticals
NEW YORK, March 6, 2017 — WinterWyman Executive Search has placed Anna O’Driscoll as Senior Director of Human Resources at Alnylam Pharmaceuticals, the leading RNAi therapeutics company. WinterWyman Executive Search’s Senior Vice President and Partner Beverly Morgan led the search.
As Alnylam’s Senior Director of Human Resources, O’Driscoll will join a high-functioning and passionate HR team to help build an agile organization that embraces creative thinking, polite disruption and challenging the ordinary path to success. In her role, she will coach senior leaders, advise on organizational design and create a robust talent planning strategy. She will also be tasked with scaling culture including best practices in team dynamics, working in a matrix design and ensuring the organizational values are realized.
Before joining Alnylam, O’Driscoll was the Head of Talent Processes and Strategy at Shire Pharmaceuticals (NASDAQ: SHPG) where she had also held Lead Human Resources Business Partner; Associate Director, Senior Human Resources Business Partner; and Manager, Human Resources Business Partner roles. Before her career at Shire, O’Driscoll worked in the Human Resources Leadership Development Program at Johnson & Johnson (NYSE: JNJ). She was also a Senior Project Manager, Learning Strategy Consulting for Pulse Learning and a Business Development Executive with Deloitte. O’Driscoll holds her MBA from Boston College.
Alnylam (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. By the end of 2020, Alnylam expects to achieve a company profile with three marketed products, 10 RNAi therapeutic clinical programs – including four in late stages of development – across its three STArs.
About WinterWyman Executive Search
WinterWyman Executive Search is a leading boutique retained search firm and authority on executive hiring for venture-backed, growth stage and large public companies. Learn more at wwexecutivesearch.com.
Executive Vice President of Marketing